Compare DexCom, Inc. (DXCM) vs Koninklijke Philips NV (PHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Koninklijke Philips NV — how do they compare? DexCom, Inc. trades at $77.98 (market cap $28.06B), while Koninklijke Philips NV trades at $27.26 (market cap $26.29B). The key difference: DexCom, Inc. and Koninklijke Philips NV are close in size by market cap, and Koninklijke Philips NV pays a 3.75% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | PHG | |
|---|---|---|
Market Cap | $28.06B | $26.29B |
Sector | Health | Health |
52-Week High | $89.53 | $32.91 |
52-Week Low | $54.84 | $24.38 |
Enterprise Value | $27.03B | $32.56B |
Dividend Yield | — | 3.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
PHG trades at $27.16, up 4.22% today. The stock shows mixed signals with a bearish technical outlook but improving fundamentals, including a return to profitability in 2025 with net income of $895 million. Recent news highlights AI integration in healthcare products and new FDA clearances, supporting growth initiatives. Analyst consensus is divided with 41% buy ratings amid neutral sentiment.
The outlook is cautiously optimistic given earnings recovery and strategic partnerships, but risks include high debt levels and competitive pressures. The stock presents a value opportunity if operational improvements continue, though technical weakness suggests near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →
